For 18 years, Truffle Capital has been creating and financing to success radical and disruptive innovations in two fields of expertise, Life Sciences and Information Technologies. These creations revolutionize their sectors and will become the tomorrow’s leaders.
Truffle Capital is the only European Fund to support its innovations from creation to commercial success.
Truffle Capital works closely with the world's best 50 universities to select and transform their most significant inventions into major technological innovations, novel medical devices and effective drug treatments.
In terms of Information technologies, Truffle Capital has focused in FinTechs since 2014. Thanks to its team of dedicated experts, Truffle is able to select products & services with underlying complex technologies (deep tech).
Truffle launchs the Fintech 100, a ranking of French fintechs and insurtechs
Creation of the Fintech 100 ranking, in partnership with Finance Innovation, Groupe BPCE, Sopra Steria Group and Sopra Banking Software
OBAT, a new investment
Digitizing invoicing and payment for SMEs in the construction sector
Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway
A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog the small company right into mid-stage testing...
Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out
Finding a functional cure to HIV is one of the biggest challenges in modern medicine...
Carmat sells its artificial heart for the first time in Italy
The autonomous bioprosthesis created by the French firm has been implanted on a patient in Naples.
Philippe Pouletty appears in Stanford OTL - 50th Anniversary Annual Report
Philippe Pouletty and his work on polymerase chain reaction (PCR) is featured in the Stanford OTL 50th Anniversary Annual Report